The purpose of the present study is the preparation and characterization of collagen/antitumor drug hybrids as drug delivery systems. Materials used for obtaining collagen-based drug delivery systems were collagen type I (Coll) as matrix and irinotecan (I) as hydrophilic active substances. After incorporation of I into Coll in differing ratios, the obtained hybrid materials (Coll/I) could be used according to our results as potential drug delivery systems in medicine for the topical (local) treatment of cancerous tissues or bone. The released amount of I varies with amount of Coll from hybrid materials: the higher, the slower the release amount of irinotecan transferred is in the first 6 hours. The in vitro citotoxicity demonstrates an antitumoral activity of the obtained hybrid materials and their potential use for biomedical applications as drug delivery systems in tumoral treatments. <alternatives> [...] </alternatives>
 X. Ding, A.W.G. Alani, J.R. Robinson, Extended release and targeted drug delivery system. In: D.B. Troy, Remington, The Science and Practice of Pharmacy, 21st edition (Lipincott Williams and Wilkins, Philadelphia, 2006)
 W. Friess, in: D.M. Brown (Ed.), Biopolymers for parenteral drug delivery in cancer treatment. Drug delivery systems in cancer therapy (Humana Press Inc., Totowa, NJ, 2004)
 N. Ahmed, C.E. Mora-Huertas, C. Jaafar-Maalej, H. Fessi, A. Elaissari, in: D. Douroumis, A. Fahr (Eds.), Polymeric drug delivery systems for encapsulating hydrophobic drugs. Drug delivery strategies for poorly water-soluble drugs (John Wiley & Sons Ltd, Oxford, UK, 2013)
Financed by the National Centre for Research and Development under grant No. SP/I/1/77065/10 by the strategic scientific research and experimental development program:
SYNAT - “Interdisciplinary System for Interactive Scientific and Scientific-Technical Information”.